Downregulation of HLA Class I Expression through HLA-A DNA Methylation Is Associated with Reduced CD8+ T-cell Infiltration in Cervical Cancer
Human leukocyte antigen class I (HLA-I) is central to tumor immune recognition, but its regulatory mechanisms in cervical cancer remain poorly understood. This study aimed to elucidate the impact of HLA-I regulatory mechanisms on CD8+ T-cell infiltration and identify distinct histotype-specific immune escape strategies across cervical cancer subtypes. Using 98 cervical cancer cases, including squamous cell carcinoma (SCC; n = 53), adenocarcinoma (n = 32), gastric-type adenocarcinoma (GAS; n = 5), small cell carcinoma (Small, n = 4), and mixed histologic types (n = 4), we examined the relationship between CD8+ T-cell infiltration patterns (categorized as infiltrated, excluded, or absent) and HLA-I expression, HLA-A DNA methylation, and HLA-I loss of heterozygosity (LOH). CD8+ T-cell infiltration patterns varied significantly by histologic subtype (P < 0.0001). SCC showed the highest frequency of the infiltrated pattern (73.6%), whereas GAS and Small predominantly displayed an absent pattern. Reduced CD8+ T-cell infiltration correlated with poor survival (P < 0.0001). HLA-I expression mirrored these trends being highest in SCC and lowest in Small and GAS. HLA-A DNA methylation emerged as a key driver of HLA-I downregulation, leading to reduced CD8+ infiltration (P < 0.05). In SCC, both HLA-A methylation and HLA-I LOH contributed to immune evasion; cases lacking these alterations exhibited the highest CD8+ T-cell infiltration levels (P < 0.01). This study identifies distinct HLA-I regulatory mechanisms in cervical cancer, highlighting HLA-A methylation-and particularly HLA-I LOH in SCC-as key drivers of immune evasion. These findings provide a foundation for developing predictive biomarkers and suggest that targeting these specific HLA-I regulatory mechanisms could enhance immunotherapy efficacy.
Authors
- Misako Kusakabe (ORCID: https://orcid.org/0009-0002-8670-617X)
- Iwao Kukimoto (ORCID: https://orcid.org/0000-0001-9080-1642)
- Katsutoshi Oda (ORCID: https://orcid.org/0000-0002-2468-9573)
- Tetsuo Ushiku (ORCID: https://orcid.org/0000-0002-1763-8380)
- Hiroko Matsunaga (ORCID: https://orcid.org/0000-0002-1725-3333)
- Yasushi Hirota (ORCID: https://orcid.org/0000-0003-0241-9780)
- Michiaki Hamada (ORCID: https://orcid.org/0000-0001-9466-1034)
- Haruko Takeyama (ORCID: https://orcid.org/0000-0002-2058-8185)
- Masahito Kawazu (ORCID: https://orcid.org/0000-0003-4146-3629)
- Yutaka Osuga (ORCID: https://orcid.org/0000-0002-6660-1066)
- Ayumi Taguchi (ORCID: https://orcid.org/0000-0002-5491-3871)
- Hitoshi Iuchi (ORCID: https://orcid.org/0000-0002-2278-3443)
- Masako Ikemura (ORCID: https://orcid.org/0000-0002-7148-778X)
- A. Ishizaka (ORCID: https://orcid.org/0009-0005-1981-4017)
- Takayuki Iriyama (ORCID: https://orcid.org/0000-0001-7970-6695)
- Kenbun Sone (ORCID: https://orcid.org/0000-0002-7218-6401)
- A. Duong (ORCID: https://orcid.org/0009-0002-4143-4465)
- Yoko Yamamoto (ORCID: https://orcid.org/0009-0009-4168-8351)
- K. Tamai (ORCID: https://orcid.org/0009-0007-3863-0701)
- S. Kitamura (ORCID: https://orcid.org/0009-0008-1464-4364)
- Ayako Mori (ORCID: https://orcid.org/0009-0006-2389-0271)
- A. Takase (ORCID: https://orcid.org/0009-0006-1421-8774)
- Daisuke Yoshimoto (ORCID: https://orcid.org/0009-0005-3555-2133)
Institutions
- Waseda University (JP)
- National Institute of Infectious Diseases (JP)
- University of Tokyo Hospital (JP)
- Chiba Cancer Center (JP)
- National Cancer Research Institute (GB)
- The University of Tokyo (JP)
- Teikyo University (JP)
Publication Details
- Journal
- Cancer Immunology Research
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1158/2326-6066.cir-25-0594
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Japan Agency for Medical Research and Development
- University of Tokyo
- Japan Society for the Promotion of Science